# The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

> **NCT03562169** · PHASE3 · RECRUITING · sponsor: **University of Leeds** · enrollment: 406 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib, thalidomide, & dexamethasone (ITD) re-induction
- **DRUG:** Conventional autologous stem cell transplant (ASCT-con)
- **DRUG:** Augmented autologous stem cell transplant (ASCT-aug)
- **DRUG:** ITD consolidation and ixazomib maintenance vs. No further therapy

## Key facts

- **NCT ID:** NCT03562169
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-03-20
- **Primary completion:** 2026-03
- **Final completion:** 2027-03
- **Target enrollment:** 406 (ESTIMATED)
- **Last updated:** 2018-06-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03562169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03562169, "The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03562169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*